Literature DB >> 8102666

Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.

T T Aoki1, M M Benbarka, M C Okimura, M A Arcangeli, R M Walter, L D Wilson, M P Truong, A R Barber, L F Kumagai.   

Abstract

An important defect in insulin-dependent diabetes mellitus (IDDM) is that the liver does not meet its full fuel-processing function, because many of the enzymes involved depend on high insulin concentrations in the portal vein. We tried to reactivate the liver by long-term treatment of IDDM patients with intravenous insulin in pulses, with the aim of achieving high portal-vein concentrations during and after a glucose meal. We studied 20 IDDM patients with brittle disease; despite use of a four-injection regimen with manipulation of insulin doses, diet, and physical activity, and frequent clinic visits for at least a year, these patients still had wide swings in blood glucose and frequent hypoglycaemic reactions. The intermittent therapy consisted of 7-10 pulses of intravenous insulin, infused while the patient was ingesting carbohydrate, primarily glucose, during the first hour of a 3 h treatment; three treatments were given in a day. After 2 consecutive days' treatment, patients were treated for 1 day per week. No patient was withdrawn from the study. At the time of this analysis the duration of intermittent treatment ranged from 7 to 71 months (mean 41 [SE 5] months). Haemoglobin A1C concentrations declined from 8.5 (0.4)% at the end of the stabilisation phase to 7.0 (0.2)% at the analysis point (p = 0.0003). During the same time the frequencies of major and minor hypoglycaemic events also fell significantly (major 3.0 [1.1] to 0.1 [0], minor 13.0 [2.6] to 2.4 [0.8] per month; both p < 0.0001). Because the use of saline rather than insulin pulses would have led to unacceptable hyperglycaemia we opted for a historical control design. The absence of a true control group limits the interpretation of these preliminary results, but we believe further studies of hepatic and muscle metabolism before and after long-term intermittent intravenous insulin therapy would be worth while.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102666     DOI: 10.1016/0140-6736(93)91645-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Value of monitoring serum procalcitonin in neonates at risk of infection.

Authors:  M M Koskenvuo; K Irjala; A Kinnala; O Ruuskanen; P Kero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

2.  Left ventricular mass reduction in type 1 diabetic patients with nephropathy.

Authors:  Larry A Weinrauch; Andrew Burger; Ray E Gleason; Annette T Lee; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-03       Impact factor: 3.738

3.  Diabetic microvascular complications: possible targets for improved macrovascular outcomes.

Authors:  John A D'Elia; George Bayliss; Bijan Roshan; Manish Maski; Ray E Gleason; Larry A Weinrauch
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-12-22

4.  Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.

Authors:  Mark F McCarty
Journal:  Healthcare (Basel)       Date:  2017-03-14

Review 5.  Effects of Periodic Intensive Insulin Therapy: An Updated Review.

Authors:  Shu Dong; Hien Lau; Cody Chavarria; Michael Alexander; Allison Cimler; John P Elliott; Sandra Escovar; Jack Lewin; James Novak; Jonathan R T Lakey
Journal:  Curr Ther Res Clin Exp       Date:  2019-04-30

Review 6.  Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology.

Authors:  Frank Greenway; Brian Loveridge; Richard M Grimes; Tori R Tucker; Michael Alexander; Scott A Hepford; Justin Fontenot; Candi Nobles-James; Carol Wilson; Adam M Starr; Mohammed Abdelsaid; Stanley T Lewis; Jonathan R T Lakey
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.